MSD & Kyowa Question NICE’s Processes After English Funding Rejected For Rare Disease Drugs

MSD and Kyowa Kirin have separately criticized England’s HTA body, NICE, for assessing their respective rare disease medicines Welireg and Crysvita using its standard appraisal pathway. Both medicines were provisionally rejected for reimbursement.

Balance scales with capsules pills and money coins. 3d render.
• Source: Alamy

MSD’s rare disease drug Welireg (belzutifan) had appeared to be on track for expedited market access in the UK, after it received the first ever “innovation passport” from the medicines agency, the MHRA, in 2021, followed by regulatory approval under the Project Orbis initiative a year later.

However, the company’s market access plans could be derailed after England’s health technology assessment (HTA) body NICE provisionally rejected the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography